Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsReceivables RefundsShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Gsk (GLAXF) Other Gross PP&E Adjustments (2019 - 2025)

Historic Other Gross PP&E Adjustments for Gsk (GLAXF) over the last 7 years, with Q3 2025 value amounting to -$1.1 billion.

  • Gsk's Other Gross PP&E Adjustments rose 235.15% to -$1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 billion, marking a year-over-year increase of 235.15%. This contributed to the annual value of -$1.1 billion for FY2024, which is 721.1% up from last year.
  • Latest data reveals that Gsk reported Other Gross PP&E Adjustments of -$1.1 billion as of Q3 2025, which was up 235.15% from -$1.1 billion recorded in Q2 2025.
  • Gsk's 5-year Other Gross PP&E Adjustments high stood at -$134.2 million for Q1 2022, and its period low was -$1.2 billion during Q4 2023.
  • For the 5-year period, Gsk's Other Gross PP&E Adjustments averaged around -$944.8 million, with its median value being -$1.0 billion (2025).
  • As far as peak fluctuations go, Gsk's Other Gross PP&E Adjustments skyrocketed by 8769.78% in 2022, and later tumbled by 49424.14% in 2023.
  • Over the past 5 years, Gsk's Other Gross PP&E Adjustments (Quarter) stood at -$997.5 million in 2021, then grew by 19.22% to -$805.8 million in 2022, then crashed by 44.32% to -$1.2 billion in 2023, then increased by 6.63% to -$1.1 billion in 2024, then rose by 1.85% to -$1.1 billion in 2025.
  • Its last three reported values are -$1.1 billion in Q3 2025, -$1.1 billion for Q2 2025, and -$1.0 billion during Q1 2025.